>
Three Bob Ross Paintings Sold for $600,000 at Auction in Fundraiser for Public Television
New Gel Regrows Dental Enamel–Which Humans Cannot Do–and Could Revolutionize Tooth Care
Delta Airlines Treats Teens to Free 'Dream Flights' Inspiring Many to Become Pilots and Engi
"Every reserve currency has COLLAPSED, the US dollar is next" We better buckle up!
Blue Origin New Glenn 2 Next Launch and How Many Launches in 2026 and 2027
China's thorium reactor aims to fuse power and parity
Ancient way to create penicillin, a medicine from ancient era
Goodbye, Cavities? Scientists Just Found a Way to Regrow Tooth Enamel
Scientists Say They've Figured Out How to Transcribe Your Thoughts From an MRI Scan
SanDisk stuffed 1 TB of storage into the smallest Type-C thumb drive ever
Calling Dr. Grok. Can AI Do Better than Your Primary Physician?
HUGE 32kWh LiFePO4 DIY Battery w/ 628Ah Cells! 90 Minute Build
What Has Bitcoin Become 17 Years After Satoshi Nakamoto Published The Whitepaper?

Company milestones are starting to make the possibilities of their respective technologies, which once seemed far off, appear as though they are in reach, according to a new report.
For example, in September, Neuralink gained FDA approval to fast-track its Blindsight vision tech, while last month, Science, led by former Neuralink President Max Hodak, reported clinical trial success in restoring vision for age-related macular degeneration.
Backed by growing investor interest and regulatory support, startups like Science ($150M raised) and Neuralink ($600M raised) are advancing brain-computer vision technology, according to Yahoo/Bloomberg.
Hodak told Bloomberg: "Restoring vision to patients will be the first killer app."
Science reported that 32 of 38 patients in its study experienced significant vision improvements, reading an average of five lines lower on an eye chart, with one patient improving by nearly 12 lines.
The Yahoo/Bloomberg report says that startups restoring sight are exploring diverse approaches.
Science is developing Prima, a retinal implant offering vision improvements through an 80-minute outpatient procedure. It complements future brain-based devices and has FDA breakthrough status, like Neuralink's Blindsight.
While retinal implants show promise, some researchers aim for visual cortex implants, which could address severe retinal or optical nerve damage with greater resolution. Competing technologies, like cell therapy, are also advancing, with companies like Cellino raising significant funds.
Though sight restoration via electrodes often results in blurry flashes, patients report life-enhancing benefits. Neuralink's Blindsight aims to implant electrodes in the visual cortex, promising ambitious advancements as patient trials progress.
Neuralink President DJ Seo concluded on a podcast earlier this year. He spoke about the potential for a glasses-and-electrode system that could eventually go beyond treating blindness: "We're currently limited by our biology in terms of the wavelength that we can see. But when you have an external camera with this BCI system, you're not limited to that."
"You can have infrared, you can have UV, you can have whatever other spectrum that you want to see," he concluded.